Tamsulosin Hydrochloride Capsule
Product Images NDC 72603-115

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 72603-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tamsulosin Fig1)

A line graph illustrating the mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours following a single 0.4 mg capsule dose under fasted and fed conditions. The x-axis represents time in hours, and the y-axis shows plasma concentration in ng/mL. Two lines compare concentration changes for fasted (dashed line) and fed (solid line) states in eight subjects.*

FDA Label Image

Figure (Tamsulosin Fig2)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' illustrating mean symptom score changes over a 13-week treatment period. The x-axis shows treatment duration in weeks, while the y-axis represents mean change scores. Three treatment groups are compared: 0.8 mg, 0.4 mg, and placebo, with all groups showing a decrease in symptom scores over time, the 0.8 mg group showing the greatest reduction.*

FDA Label Image

Figure (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change on the vertical axis and duration of treatment in weeks on the horizontal axis. It compares three treatments: 0.8 mg and 0.4 mg dosage groups, and placebo, with sample sizes noted below the timeline. The graph demonstrates trends in symptom score changes over 13 weeks, with the 0.8 mg and 0.4 mg lines showing greater decreases compared to placebo.*

FDA Label Image

Figure (Tamsulosin Fig4)

Line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in urine flow rate over treatment duration in weeks. Three treatment groups are plotted: 0.8 mg, 0.4 mg, and placebo, with 0.8 mg and 0.4 mg showing larger increases in flow rate compared to placebo across the study period.*

FDA Label Image

Figure (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2,' showing mean change in urine flow rate over treatment duration in weeks. It compares three treatments: 0.8 mg and 0.4 mg dosages (Tamsulosin Hydrochloride) and placebo, with number of subjects at each time point noted below the x-axis.*

FDA Label Image

Package Label-principal Display Panel (0.4 mg (100 Capsules Bottle))

Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg, containing 100 capsules. Manufactured for Northstar Rx LLC, Memphis, TN, and by Aurobindo Pharma Limited, India. The label includes storage instructions, dosage form, and barcode. It specifies the product is of Indian origin with an issued date of 08/2022.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing the molecular arrangement including aromatic rings, functional groups, and the hydrochloride component as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.